American Cancer Society Colorectal Cancer Survivorship Care Guidelines

El-Shami, Khaled; Oeffinger, Kevin C.; Erb, Nicole L.; Willis, Anne; Bretsch, Jennifer K.; Pratt-Chapman, Mandi; Cannady, Rachel; Wong, Sandra L.; Rose, Johnie; Barbour, April; Stein, Kevin; Sharpe, Katherine; Brooks, Durado; Cowens-Alvarado, Rebecca

doi:10.3322/caac.21286

Cited by 356 publications

(345 citation statements)

References 153 publications

(312 reference statements)

Supporting

Mentioning

316

Contrasting

Unclassified

Order By: Relevance

“…Colorectal cancer (CRC) is one of the most frequent malignancies in the world and the leading cause of cancer-related mortality [1,2]. CRC is a highly heterogeneous disease with diverse genetic and clinical manifestations which can have significant impacts on therapeutic outcomes [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

SNHG6 Promotes Tumor Growth via Repression of P21 in Colorectal Cancer

Qiu

Qiu³

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: SNHG6 (Small Nucleolar RNA Host Gene 6) is a novel non-coding RNA (ncRNA) and its cellular function is largely unknown. Methods: Cell Counting Kit-8 (CCK-8) cell growth assay, colony formation and flow cytometry were used to determine colorectal cancer cell proliferation, cell cycle progression and apoptosis in vitro. The xenograft tumor formation assay in nude mice was established to evaluate tumor growth in vivo. RNA immunopreciptation (RIP) analysis was performed to examine whether SNHG6 could bind to EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit), and chromatin immunoprecipitation (ChIP) assay was conducted to examine whether SNHG6 could repress p21 transcription by recruiting EZH2 to the p21 promoter. Results: Here we found that SNHG6 was upregulated and its expression levels were positively correlated with advanced tumor stage in colorectal cancer. Survival analysis suggested that higher expression of SNHG6 predicted poor prognosis in patients with colorectal cancer. Functional studies indicated that SNHG6 could promote cell proliferation via a direct suppression of p21 expression in colorectal cancer cells. Moreover, SNHG6 repressed p21 transcription through recruiting EZH2 to the p21 promoter in colorectal cancer cells. Conclusion: Taken together, our study demonstrates that SNHG6 promotes tumor growth via repression of p21 in colorectal cancer, which may provide a promising target for novel anticancer therapeutics.

show abstract

Section: Introductionmentioning

confidence: 99%

SNHG6 Promotes Tumor Growth via Repression of P21 in Colorectal Cancer

Qiu

Qiu³

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…The rationales for these recommendations stem from observational studies and clinical trials that have shown improved progression-free and overall survival rates for those found to have liver or lung metastases who have undergone metastasectomies. 4,5 The guidelines [1][2][3]6 also recommend a surveillance colonoscopy at 1 year following surgery. This has two goals: to remove metachronous lesions which may arise rapidly after the initial resection or which may represent missed lesions; [7][8][9][10][11] and to identify anastomotic recurrences which may develop in up to 4% of patients.…”

Section: Introductionmentioning

confidence: 99%

Adherence to colonoscopy at 1 year following resection of localized colon cancer: a retrospective cohort study

Neugut

Zhong

Lebwohl

et al. 2018

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: For patients with stages I-III colon cancer who have undergone surgical resection, guidelines recommend surveillance colonoscopy at 1 year. However, limited data exist on adherence and associated factors. We aimed to determine the rate of adherence to surveillance colonoscopy at 1 year among nonmetastatic colon cancer patients who underwent resection and factors associated with adherence. Methods: In this population-based retrospective cohort study, the Surveillance, Epidemiology, and End Results (SEER)-Medicare database was used. We identified patients with stages I-III colon cancer who underwent surgical resection and survived >3 years without recurrence (no chemotherapy after 8 months) from 2002-2011. Our primary outcome was a colonoscopy claim 10-15 months after resection. We used multivariable regression analysis to assess associations between sociodemographic and clinical factors and receipt of timely colonoscopy. Results: Among 28,732 patients who survived >3 years without recurrence, 7967 (28%) did not undergo colonoscopy; 12,033 (42%) had it at one year, with 3159 (11%) before 10 months and 5573 (19%) after 15 months. Decreased adherence was associated with older age; being male versus female; being black or Hispanic versus white; higher tumor stage; left-sided tumors versus right sided; and increased comorbidities. Chemotherapy receipt was associated with increased adherence (odds ratio 2.06; 95% confidence interval 1.88-2.24). Conclusions:In a large population-based sample of individuals aged ⩾ 65 years, only 42% of colon cancer survivors underwent 1-year surveillance colonoscopy. Demographic and clinical factors were associated with adherence.

show abstract

“…Survivor transitions to primary care are made feasible by Canada's publicly funded health care system, which ensures the provision of survivorship care regardless of setting. An initial pilot population of colorectal cancer and lymphoma survivors were chosen because of their relatively well-identified survivorship and care coordination needs 20,21 . The tcc applies the most recent evidence-based guidelines and best practices identified by group consensus at the Odette Cancer Centre, such as the provision of treatment summaries and survivorship care plans (scps) 3 .…”

Section: Introductionmentioning

confidence: 99%

The Experiences of Cancer Survivors While Transitioning from Tertiary to Primary Care

et al. 2016

View full text Add to dashboard Cite

PurposeIn current fiscally constrained health care systems, the transition of cancer survivors to primary care from tertiary care settings is becoming more common and necessary. The purpose of our study was to explore the experiences of survivors who are transitioning from tertiary to primary care. MethodsOne focus group and ten individual telephone interviews were conducted. Data saturation was reached with 13 participants. All sessions were audio-recorded, transcribed verbatim, and analyzed using a qualitative descriptive approach.Results Eight categories relating to the main content category of transition readiness were identified in the analysis. Several factors affected participant transition readiness: how the transition was introduced, perceived continuity of care, support from health care providers, clarity of the timeline throughout the transition, and desire for a "roadmap." Although all participants spoke about the effect of their relationships with health care providers (tertiary, transition, and primary care), their relationship with the primary care provider had the most influence on their transition readiness. ConclusionsOur study provided insights into survivor experiences during the transition to primary care. Transition readiness of survivors is affected by many factors, with their relationship with the primary care provider being particularly influential. Understanding transition readiness from the survivor perspective could prove useful in ensuring patient-centred care as transitions from tertiary to primary care become commonplace.

show abstract

American Cancer Society Colorectal Cancer Survivorship Care Guidelines

Cited by 356 publications

References 153 publications

SNHG6 Promotes Tumor Growth via Repression of P21 in Colorectal Cancer

SNHG6 Promotes Tumor Growth via Repression of P21 in Colorectal Cancer

Adherence to colonoscopy at 1 year following resection of localized colon cancer: a retrospective cohort study

The Experiences of Cancer Survivors While Transitioning from Tertiary to Primary Care

Contact Info

Product

Resources

About